Bristol Myers pledges to sell its Acceleron shares as activist investors circle Merck’s $11.5B buyout — report

Just as Avoro Capital’s campaign to derail Merck’s proposed $11.5 billion buyout of Acceleron gains steam, Bristol Myers Squibb is leaning in with some hefty counterweight.

The pharma giant is planning to tender its Acceleron shares, Bloomberg reported, which add up to a sizable 11.5%...

Click to view original post